Endologix, Inc. announced the presentation of positive 3-year clinical data from the Ovation European Post Market Registry at the 2017 Leipzig Interventional Course (LINC Symposium) in Leipzig, Germany. The Ovation European Post Market Registry included a total of 501 patients, enrolled across 30 European centers from May 2011 to December 2013. Through three years of follow-up, key highlights of the study results included: Broadest range of patient applicability on IFU of all commercially available infrarenal endovascular AAA devices; 99% freedom from aneurysm-related mortality; 99% freedom from migration, rupture, and conversion; 97% freedom from Type I/III endoleak; and excellent freedom from secondary intervention for occlusion (97%), Type I endoleak (97%) and Type II endoleak (95%).